Polycystic liver disease genes: Practical considerations for genetic testing.
ADPLD
Clinical value
Genetic testing
Polycystic liver
Journal
European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
25
11
2020
revised:
26
01
2021
accepted:
31
01
2021
pubmed:
9
2
2021
medline:
6
7
2021
entrez:
8
2
2021
Statut:
ppublish
Résumé
The development of a polycystic liver is a characteristic of the monogenic disorders: autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), and autosomal dominant polycystic liver disease (ADPLD). Respectively two and one genes mainly cause ADPKD and ARPKD. In contrast, ADPLD is caused by at least six different genes which combined do not even explain the disease development in over half of the ADPLD population. Genetic testing is mainly performed to confirm the likelihood of developing PKD and if renal therapy is essential. However, pure ADPLD patients are frequently not genetically screened as knowledge about the genotype-phenotype correlation is currently limited. This paper will clarify the essence of genetic testing in ADPLD patients.
Identifiants
pubmed: 33556586
pii: S1769-7212(21)00026-4
doi: 10.1016/j.ejmg.2021.104160
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
104160Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.